SCICLONE PHARMACEUTICALS, INC. CHANGE IN CONTROL AGREEMENTChange in Control Agreement • August 9th, 2013 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • California
This Change in Control Agreement (the “Agreement”) is effective as of July 16, 2013, by and between Wilson Cheung (the “Employee”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
SCICLONE PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • August 9th, 2013 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Severance Agreement (the “Agreement”) is effective as of July 16, 2013, by and between Wilson Cheung (the “Executive”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
FRAMEWORK AGREEMENTFramework Agreement • August 9th, 2013 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This framework agreement (this “Agreement”) provides an outline for the terms of an agreement contemplated to be signed by Zensun (Shanghai) Science & Technology Co., Ltd. (“Zensun”) and SciClone Pharmaceuticals International China Holding Ltd. or its designated affiliate (“SciClone”). Subject to the provisions hereof, the parties agree to be bound by the terms of this Agreement and to negotiate more detailed terms with a view to entering into a supplemental license and supply agreement (the “Supplemental Agreement”) for the promotion, marketing, distribution and sale of the Product in the Territory (each as defined below), on substantially the terms set forth below. The parties intend to complete and execute the Supplemental Agreement on or before [***] but intend to be bound by the terms of this Agreement whether or not a further agreement is entered into.
FRAMEWORK AGREEMENTFramework Agreement • August 9th, 2013 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Framework Agreement (“Agreement”), dated as of 25 June 2013 (the “Agreement Effective Date”) provides a summary of the terms of an agreement to be signed by Taiwan Liposome Company (“TLC”) and SciClone Pharmaceuticals International China Holding Ltd. or its designated affiliate (“SciClone”). Subject to the provisions hereof, the parties agree to be bound by the terms of this Agreement and to use their [***], commencing promptly after the Agreement Effective Date, to negotiate more detailed terms with a view to entering into a mutually acceptable supplemental license and supply agreement (the “Supplemental Agreement”) for the promotion, marketing, distribution and sale of the Product in the Territory (both as defined below) and Manufacturing and Supply Agreement, on substantially the terms set forth below. The parties intend to finalize and execute the Supplemental Agreement on or before [***] but intend to be bound whether or not a further agreement is entered into.
